Bridgewater Associates’s Apellis Pharmaceuticals APLS Stock Holding History

Bridgewater Associates’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,913	Closed	-$1.4M	–	1014
2026 Q1	$1.4M	Sell	34,913 -108,892	-76%	-$2.35M	0.01%	725
2025 Q4	$3.61M	Buy	+143,805	New	+$3.37M	0.01%	619

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridgewater Associates's APLS Position: Q2 2026 in Review

Bridgewater Associates sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 34,913 shares — an estimated $1.4M sold.

Bridgewater Associates first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $3.61M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Bridgewater Associates reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bridgewater Associates sold 34,913 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.4M.
Bridgewater Associates first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Bridgewater Associates's Apellis Pharmaceuticals position peaked at $3.61M in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.